Population-Based Evaluation of Vaccine Effectiveness against SARS-CoV-2 Infection, Severe Illness, and Death, Taiwan

Population-Based Evaluation of Vaccine Effectiveness against SARS-CoV-2 Infection, Severe Illness, and Death, Taiwan

Taiwan provided several COVID-19 vaccine platforms: mRNA (BNT162b2, mRNA-1273), adenoviral vector-based (AZD1222), and protein subunit (MVC-COV1901). After Taiwan shifted from its zero-COVID strategy in April 2022, population-based evaluation of vaccine effectiveness (VE) became possible. We conduc...

Full description

Bibliographic Details
Main Authors: Cheng-Yi Lee, Hung-Wei Kuo, Yu-Lun Liu, Jen-Hsiang Chuang, Jih-Haw Chou
Format: Article
Language:English
Published: Centers for Disease Control and Prevention 2024-03-01
Series:Emerging Infectious Diseases
Subjects:
COVID-19
respiratory infections
severe acute respiratory syndrome coronavirus 2
SARS-CoV-2
SARS
coronavirus disease
Online Access:https://wwwnc.cdc.gov/eid/article/30/3/23-0893_article

Internet

https://wwwnc.cdc.gov/eid/article/30/3/23-0893_article

Similar Items